title: Can first-trimester screening program detect women at high risk for gestational diabetes mellitus?
abstract: This study was designed to compare first-trimester maternal serum biochemical markers of aneuploidy and fetal nuchal translucency in pregnancies complicated by gestational diabetes mellitus and those of a control group. The study included 60 gestational diabetic and 60 control women who attended the first-trimester combined screening program for Down syndrome between 11 and 14 gestational weeks with complete follow-up data and delivered in our institution. Maternal serum free β-human chorionic gonadotropin, pregnancy-associated plasma protein-A and fetal nuchal translucency were investigated. The combined risks, double test risks and age risks were calculated by PRISCA software version 4.0. Comparison of the results between the two groups yielded no significant differences in serum levels of free β-human chorionic gonadotropin and fetal nuchal translucency. However, women who developed gestational diabetes mellitus had significantly lower pregnancy-associated plasma protein-A. And also, the combined risks and double test risks calculated by PRISCA software were statistically higher in gestational diabetic women than normal pregnant women. These results suggest that differences can be seen between diabetic and healthy pregnant women in first-trimester maternal serum biochemical markers of aneuploidy.
authors.affiliation: Department of Biochemistry, Baskent University School of Medicine, Ankara, Turkey. sevsenk@yahoo.com
authors.forename: Sevsen
authors.initials: S
authors.lastname: Kulaksizoglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kulaksizoglu
authors.forename: Ayse Gul
authors.initials: AG
authors.lastname: Kebapcilar
authors.forename: Ayse Nur
authors.initials: AN
authors.lastname: Torun
authors.forename: Emel
authors.initials: E
authors.lastname: Ozcimen
authors.forename: Suna
authors.initials: S
authors.lastname: Turkoglu
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D016640:Diabetes, Gestational / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D015536:Down-Regulation; D042241:Early Diagnosis; D005260:Female; D005500:Follow-Up Studies; D006786:Hospitals, Urban; D006801:Humans; D015994:Incidence; D048208:Nuchal Translucency Measurement / Q000009:adverse effects; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis*; D011296:Prenatal Diagnosis / Q000009:adverse effects; D012189:Retrospective Studies; D012306:Risk; D014421:Turkey / Q000453:epidemiology
chemical_list: D015415:Biomarkers; D018997:Chorionic Gonadotropin, beta Subunit, Human; D011266:Pregnancy-Associated Plasma Protein-A; C579283:PAPPA protein, human